COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND

被引：0
作者：
Prasongsook, Naiyarat [1 ]
Jaruhathai, Sureerat [1 ]
Maoleekulpairoj, Savitree [1 ]
Sooksriwong, Chaoncin [1 ]
机构：
[1] Mahidol Univ, Fac Pharm, Bangkok 10700, Thailand
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
TK1; Cost-effectiveness; gefitinib; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1245 / S1246
页数：2
相关论文
共 50 条
[31]   THE THERAPEUTIC OUTCOMES OF ERLOTINIB AFTER FAILURE OF GEFITINIB FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER [J].
Matsunami, Keiji ;
Matsumoto, Shingo ;
Suyama, Hisashi ;
Kodani, Masahiro ;
Toge, Hirokazu ;
Kawasaki, Yuji ;
Igishi, Tadashi ;
Nakamura, Hiroshige ;
Shimizu, Eiji .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1241-S1241
[32]   Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer [J].
Kaira, Kyoichi ;
Naito, Tateaki ;
Takahashi, Toshiaki ;
Ayabe, Eriko ;
Shimoyama, Rai ;
Kaira, Rieko ;
Ono, Akira ;
Igawa, Satoshi ;
Shukuya, Takehito ;
Murakami, Haruyasu ;
Tsuya, Asuka ;
Nakamura, Yukiko ;
Endo, Masahiro ;
Yamamoto, Nobuyuki .
LUNG CANCER, 2010, 68 (01) :99-104
[33]   Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis [J].
Yang, Zuyao ;
Hackshaw, Allan ;
Feng, Qi ;
Fu, Xiaohong ;
Zhang, Yuelun ;
Mao, Chen ;
Tang, Jinling .
INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (12) :2805-2819
[34]   Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer [J].
Wang, Yao ;
Huang, Kaiyu ;
Sun, Sijia ;
Deng, Yahong ;
Xie, Xuefeng .
RISK MANAGEMENT AND HEALTHCARE POLICY, 2022, 15 :351-359
[35]   A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) [J].
Kim, Se Hyun ;
Shim, Hyo Sup ;
Cho, Jaeho ;
Jeong, Jae Heon ;
Kim, Sun Mi ;
Hong, Yun Kyoung ;
Sung, Ji Hee ;
Ha, Sang-Jun ;
Kim, Hye Ryun ;
Chang, Hyun ;
Kim, Joo Hang ;
Tania, Crombet ;
Cho, Byoung Chul .
LUNG CANCER, 2013, 79 (03) :270-275
[36]   Gefitinib in advanced non-small cell lung cancer [J].
Sharma, R ;
Boyer, M ;
Clarke, S ;
Millward, M .
INTERNAL MEDICINE JOURNAL, 2005, 35 (02) :77-82
[37]   Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer [J].
Zhang, Longfeng ;
Li, Na ;
Liu, Maobai ;
Zheng, Bin ;
Wu, Zhijuan ;
Cai, Hongfu .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :4263-4270
[38]   Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer [J].
Vergnenegre, Alain ;
Ray, Joshua A. ;
Chouaid, Christos ;
Grossi, Francesco ;
Bischoff, Helge G. ;
Heigener, David F. ;
Walzer, Stefan .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 :31-37
[39]   Effectiveness of Erlotinib in Advanced Non-Small Cell Lung Cancer in Cases of Gefitinib Resistance after Treatment of More Than 6 Months [J].
Saito, Haruhiro ;
Murakami, Shuji ;
Kondo, Tetsuro ;
Oshita, Fumihiro ;
Noda, Kazumasa ;
Yamada, Kouzo .
ONKOLOGIE, 2012, 35 (1-2) :18-22
[40]   Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer [J].
Kimura, M. ;
Yasue, F. ;
Usami, E. ;
Kawachi, S. ;
Iwai, M. ;
Go, M. ;
Ikeda, Y. ;
Yoshimura, T. .
MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) :201-206
12345